Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, for which aging represents the main risk factor. As the global elderly population expands, the prevalence of Alzheimer’s disease escalates rapidly. Notably, as AD brain lesions may start 15–20 years before the appearance of the first symptoms, early diagnosis or prognosis of AD is of paramount importance for better patient treatment. Based on the absence of effective cure or early diagnosis of AD, this meta-analysis investigates the differentially expressed genes between Alzheimer’s and a healthy brain and identifies genes that can serve as risk factors for the disease or biomarkers of diagnostic, prognostic, or pharmacological value. Microarray datasets were collected from public repositories, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. Quality control and data normalization were performed. Differentially expressed gene (DEG) lists were created for each study and combined through a Mosteller–Bush meta-analysis, resulting in a final list of DEGs. This list was filtered using an adjusted p-value cut-off of 0.001, and the included statistically significant DEGs were subjected to enrichment analyses. A total of eight microarray studies were identified, producing a combined list of 4218 DEGs, of which 1944 were up-regulated and enriched for immune response processes, and 2274 were down-regulated and enriched for synapse-related pathways. This meta-analysis reveals a distinct transcriptomic profile in Alzheimer’s disease characterized by the prevalence of immune response and inflammation alongside the collapse of essential synaptic and neuronal signaling.
Dermitzaki et al. (Mon,) studied this question.